Monograph Title | Section | Source Publication | Page Number | Errata Post Date | Errata Official Date | Target Errata Print Publication | Target Online Fix Publication Sort ascending | Description |
---|---|---|---|---|---|---|---|---|
AZITHROMYCIN FOR INJECTION | ADDITIONAL REQUIREMENTS | USPNF Online | Online | 28-Jul-2023 | 1-Aug-2023 | NA | USPNF 2024 Issue 2 | In USP Reference Standards 〈11〉/USP Azaerythromycin A RS: Change 734.96 to: 734.97 AND In USP Azithromycin N-oxide RS: Change 764.98 to: 765.00 AND In USP N-Demethylazithromycin RS: Change 734.96 to: 734.97… Read More |
AZITHROMYCIN FOR INJECTION | IMPURITIES | USPNF Online | Online | 28-Jul-2023 | 1-Aug-2023 | NA | USPNF 2024 Issue 2 | In footnote m in Table 2: Change (2R,3S,4R,5R,8R,10R,11R,12S,13S,14R)-13-[(2,6-Dideoxy-3-C-methyl-3-O-methyl-α-L-ribo-hexopyranosyl)oxy]-2-ethyl-3,4,10-trihydroxy-3,5,6,8,10,12,14-… Read More |
ROCURONIUM BROMIDE | CHEMICAL INFORMATION | USPNF Online | Online | 18-Nov-2022 | 1-Dec-2022 | NA | USPNF 2023 Issue 3 | Change 609.68 to: 609.69 |
ROCURONIUM BROMIDE | IMPURITIES/Organic Impurities | USPNF Online | Online | 18-Nov-2022 | 1-Dec-2022 | NA | USPNF 2023 Issue 3 | In footnote b of Table 1: Change 2β-(Morpholin-4-yl)-16β-(pyrrolidin-1-yl)-5α-androstan-3α,17β-diol. to: 2β-(Morpholin-4-yl)-16β-(pyrrolidin-1-yl)-5α-androstane-3α,17β-diol. |
METHYLENE BLUE | IMPURITIES/Organic Impurities | USPNF Online | Online | 26-Aug-2022 | 1-Sep-2022 | NA | USPNF 2023 Issue 2 | In footnote a in Table 2: Change 3-(Dimethylamino)-7-(methylamino)-phenothiazine-5-ium chloride. to: 3-(Dimethylamino)-7-(methylamino)phenothiazin-5-ium chloride. |
METHYLENE BLUE | ADDITIONAL REQUIREMENTS/USP Reference Standards <11> | USPNF Online | Online | 26-Aug-2022 | 1-Sep-2022 | NA | USPNF 2023 Issue 2 | In USP Azure B RS: Change 3-(Dimethylamino)-7-(methylamino)-phenothiazine-5-ium chloride. to: 3-(Dimethylamino)-7-(methylamino)phenothiazin-5-ium chloride. |
ECONAZOLE NITRATE | ADDITIONAL REQUIREMENTS/USP Reference Standards <11> | USPNF Online | Online | 26-Aug-2022 | 1-Sep-2022 | NA | USPNF 2023 Issue 2 | In USP Econazole Related Compound C RS: Change 1-(4-Chlorobenzyl)-3-{2-[(4-chlorobenzyl)oxy]-2-(2,4-dichlorophenyl)ethyl}-1H-imidazol-3-ium nitrate (salt). C25H21Cl14N3O4 569.… Read More |
NAPROXEN SODIUM TABLETS | IMPURITIES/Organic Impurities | First Supplement to USP41–NF36 | 8363 | 30-Nov-2018 | 1-Dec-2018 | USP43–NF38 | USP42–NF37 | In the System suitability solution: Change 0.5 mg/mL of USP Naproxen Sodium RS and 0.5 µg/mL of USP Naproxen Related Compound A RS in Diluent, from Standard stock solution 1 and Standard stock solution 2, respectively to: 0.5… Read More |
CUPRIC SULFATE INJECTION | Assay | USP41–NF36 | 1112 | 30-Nov-2018 | 1-Dec-2018 | USP43–NF38 | USP42–NF37 | Line 8 of Assay preparation: Change to bring the total sodium content of this flask to 13.5 mg. to: to bring the total sodium chloride content of this flask to 13.5 mg. |
OCTOCRYLENE | SPECIFIC TESTS/Acidity | First Supplement to USP41–NF36 | 8379 | 30-Nov-2018 | 1-Dec-2018 | USP43–NF38 | USP42–NF37 | Line 1 of Acceptance criteria: Change NMT 0.18 mL of Titrant is required to: NMT 0.18 mL of Titrant/g is required |
FLUTICASONE PROPIONATE INHALATION POWDER | IMPURITIES/Organic Impurities/System suitability | USP41–NF36 | 1836 | 30-Nov-2018 | 1-Dec-2018 | USP43–NF38 | USP42–NF37 | In the Tailing factor: Change NLT 1.3 to: NMT 1.3 |
OXYBUTYNIN CHLORIDE EXTENDED-RELEASE TABLETS | PERFORMANCE TESTS/Dissolution <711>/Test 8 | Revision Bulletin (Official April 01, 2018) | Online | 30-Nov-2018 | 1-Dec-2018 | USP43–NF38 | USP42–NF37 | In the variable definition list in Analysis: Change CS = concentration of oxybutynin chloride in the Standard solution (mg/mL) to: CS = concentration of USP Oxybutynin Chloride RS in the Standard… Read More |
GLUTARAL CONCENTRATE | ASSAY/Procedure | USP41–NF36 | 1960 | 30-Nov-2018 | 1-Dec-2018 | USP43–NF38 | USP42–NF37 | In the variable definition list in Analysis: Change W = weight of Concentrate taken (g) to: W = nominal weight of glutaral taken (g) |
LIDOCAINE | ASSAY/Procedure | First Supplement to USP41–NF36 | Online | 30-Nov-2018 | 1-Dec-2018 | USP43–NF38 | USP42–NF37 | This erratum applies to the new USP-NF ONLINE platform only. Line 2 of Standard solution: Change 1 N sodium hydroxide, to: 1 N hydrochloric acid, AND Line 2 of Sample solution: Change 1 N sodium hydroxide, to: 1 N… Read More |
AZEOTROPIC ISOPROPYL ALCOHOL | ADDITIONAL REQUIREMENTS/USP Reference Standards <11> | USP41–NF36 | 2257 | 30-Nov-2018 | 1-Dec-2018 | USP43–NF38 | USP42–NF37 | Line 1 of USP 2-Propanol System Suitability RS: Change It contains 0.1% of each of the following: ethyl ether, acetone, isopropyl alcohol, diisopropyl ether, 1-propanol, and 2-butanol. to: It is a mixture of the following: ethyl ether (0.1%), acetone (0.1… Read More |
OXYBUTYNIN CHLORIDE EXTENDED-RELEASE TABLETS | ASSAY/Procedure | Revision Bulletin (Official April 01, 2018) | Online | 30-Nov-2018 | 1-Dec-2018 | USP43–NF38 | USP42–NF37 | This erratum applies to the Revision Bulletin posted on www.uspnf.com only. In System suitability: Add [Note—The relative retention times for oxybutynin and oxybutynin related compound A are about 1.0 and 1.6,… Read More |
METOPROLOL TARTRATE | CHEMICAL INFORMATION | USP41–NF36 | 2712 | 30-Nov-2018 | 1-Dec-2018 | USP43–NF38 | USP42–NF37 | Line 4: Change (±)-1-(Isopropylamino)-3-[p-(2-methoxyethyl)phenoxy]-2-propanol l-(+)-tartrate (2:1) (salt); 1-(Isopropylamino)-3-[p-(2-methoxyethyl)phenoxy]-2-propanol (2:1) dextro-tartrate salt to: (±)-1-(… Read More |
OXYBUTYNIN CHLORIDE EXTENDED-RELEASE TABLETS | IMPURITIES/Organic Impurities | Revision Bulletin (Official April 01, 2018) | Online | 30-Nov-2018 | 1-Dec-2018 | USP43–NF38 | USP42–NF37 | This erratum applies to the Revision Bulletin posted on www.uspnf.com only. In the variable definition list in Analysis: Change CU = nominal concentration of the Sample solution (mg… Read More |
FLUTICASONE PROPIONATE AND SALMETEROL INHALATION POWDER | ADDITIONAL REQUIREMENTS/USP Reference Standards <11> | USP40–NF35 | 4309 | 30-Mar-2018 | 1-Apr-2018 | USP42–NF37 | USP42–NF37 | Line 2 of USP Salmeterol Related Compound H RS: Change 1-Hydroxy-4-[2-hydroxy-5-(1-hydroxy-2-{[6-(4-phenylbutoxy)hexyl]amino}ethyl)benzyl]-2-naphthoic acid. C36H43NO6 585.73 to: 1-Hydroxy-4-[2-hydroxy-5-(1-hydroxy-2-{[6… Read More |
PANTOPRAZOLE SODIUM DELAYED-RELEASE TABLETS | PERFORMANCE TESTS/Dissolution Test 1 | USP41–NF36 | 3157 | 30-Nov-2018 | 1-Dec-2018 | USP43–NF38 | USP42–NF37 | In the Analysis: Change Result = (rU/rS) × CS × (Mr1/Mr2) × V × (100/L) to: Result = (rU/rS) × CS × (Mr1/Mr2) × V × (100/L) × D … Read More |
PERINDOPRIL ERBUMINE | IMPURITIES/Limit of Perindopril Related Compound I/System suitability | USP40–NF35 | 5644 | 30-Mar-2018 | 1-Apr-2018 | USP42–NF37 | USP42–NF37 | Line 3: Add [Note—The relative retention times for perindopril and perindopril related compound I are 1.0 and 1.6, respectively.] |
AMLODIPINE AND ATORVASTATIN TABLETS | DEFINITION | First Supplement to USP41–NF36 | 8270 | 30-Nov-2018 | 1-Dec-2018 | USP43–NF38 | USP42–NF37 | Line 4: Change (C33H34FN2O5) to: (C33H35FN2O5) |
SALMETEROL INHALATION POWDER | ADDITIONAL REQUIREMENTS/USP Reference Standards <11> | USP40–NF35 | 6096 | 30-Mar-2018 | 1-Apr-2018 | USP42–NF37 | USP42–NF37 | Line 2 of USP Salmeterol Related Compound H RS: Change 1-Hydroxy-4-[2-hydroxy-5-(1-hydroxy-2-{[6-(4-phenylbutoxy)hexyl]amino}ethyl)benzyl]-2-naphthoic acid. C36H43NO6 585.73 to: 1-Hydroxy-4-[2-hydroxy-5-(1-hydroxy-2-{[6… Read More |
ALLOPURINOL | ADDITIONAL REQUIREMENTS/USP Reference Standards <11> | USP41–NF36 | 121 | 30-Nov-2018 | 1-Dec-2018 | USP43–NF38 | USP42–NF37 | Line 3 of USP Allopurinol Related Compound A RS: Change (C5H6N4O)2 · H2SO4 350.32 to: (C4H6N4O)2 · H2SO4 350.31 |
AMLODIPINE AND ATORVASTATIN TABLETS | ASSAY/Procedure | First Supplement to USP41–NF36 | 8270 | 30-Nov-2018 | 1-Dec-2018 | USP43–NF38 | USP42–NF37 | In the second Calculate statement in Analysis: Change (C33H34FN2O5) to: (C33H35FN2O5) |
<661.1> PLASTIC MATERIALS OF CONSTRUCTION | TEST METHODS/Tin in Non-Tin-Stabilized Materials | USP41–NF36 | 6403 | 30-Mar-2018 | 1-Apr-2018 | USP42–NF37 | USP42–NF37 | Line 3 of Sample solution: Change If the solution is not colorless, add the sodium sulfate to: If the solution is not colorless, add the sodium sulfite |
CIPROFLOXACIN AND DEXAMETHASONE OTIC SUSPENSION | IMPURITIES | USP41–NF36 | 951 | 30-Nov-2018 | 1-Dec-2018 | USP43–NF38 | USP42–NF37 | In the variable definition list of Ciprofloxacin Related Compounds/Analysis: Change CU = nominal concentration of ciprofloxacin in the Otic Suspension (mg/mL) to: CU = nominal… Read More |
AMLODIPINE AND ATORVASTATIN TABLETS | PERFORMANCE TESTS/Dissolution <711> | First Supplement to USP41–NF36 | 8270 | 30-Nov-2018 | 1-Dec-2018 | USP43–NF38 | USP42–NF37 | In the second Calculate statement in Analysis: Change (C33H34FN2O5) to: (C33H35FN2O5) AND In Tolerances: Change (C33H… Read More |
CUPRIC CHLORIDE | ASSAY/Procedure | USP41–NF36 | 1109 | 30-Nov-2018 | 1-Dec-2018 | USP43–NF38 | USP42–NF37 | Line 1 of Analysis: Change To the Sample solution to: To 50 mL of the Sample solution |
ACAMPROSATE CALCIUM | IMPURITIES/Limit of Acamprosate Related Compound A | First Supplement to USP41–NF36 | 8263 | 30-Nov-2018 | 1-Dec-2018 | USP43–NF38 | USP42–NF37 | In the variable definition list in Analysis: Change CS = concentration of USP Acamprosate Calcium Related Compound A RS in the Standard solution (µg/mL) to: CS = concentration of USP Acamprosate Related… Read More |
CUPRIC CHLORIDE INJECTION | ASSAY/Procedure | USP41–NF36 | 1111 | 30-Nov-2018 | 1-Dec-2018 | USP43–NF38 | USP42–NF37 | Line 3 of Sample solution: Change to bring the total sodium content of this flask to 13.5 mg. to: to bring the total sodium chloride content of this flask to 13.5 mg. |
<212> OLIGOSACCHARIDE ANALYSIS | SEPARATION AND IDENTIFICATION OF OLIGOSACCHARIDES | USP40–NF35 | 273 | 26-May-2017 | 1-Jun-2017 | USP41–NF36 | USP41–NF36 | Line 1 of Normal Phase Chromatography/HILIC/Ammonium formate buffer: Change Add 1.4 M ammonia solution to 1.4 M formic acid solution. to: Add 1.4 M ammonia solution to 1.4 M formic acid solution until a pH of 4.4 is obtained. |
SCAFFOLD BOVINE DERMIS | SPECIFIC TESTS | USP40–NF35 | 6113 | 26-May-2017 | 1-Jun-2017 | USP41–NF36 | USP41–NF36 | Line 5 of Carbohydrate Content/Acceptance criteria: Change Moisture Content to: Loss on Drying AND Line 3 of Suture Retention Force/Analysis: Change 40 to: 4-0 |
MYCOPHENOLATE MOFETIL FOR ORAL SUSPENSION | ADDITIONAL REQUIREMENTS/USP Reference Standards <11> | USP39–NF34 | 4961 | 31-Mar-2017 | 1-Apr-2017 | USP41–NF36 | USP41–NF36 | Line 5 of Mycophenolate Mofetil Related Compound A RS: Change C23H31NO7 to: C22H29NO7 |
ROPINIROLE EXTENDED-RELEASE TABLETS | IMPURITIES/Organic Impurities/Analysis | Second Supplement to USP39–NF34 | 8814 | 31-Mar-2017 | 1-Apr-2017 | USP41–NF36 | USP41–NF36 | Line 8 of the variable definition list of the first equation: Change CU = nominal concentration of ropinirole related compound B free base in the Sample solution (µg/mL) to: CU = nominal concentration of ropinirole in the … Read More |
<603> TOPICAL AEROSOLS | DELIVERED-DOSE UNIFORMITY | USP40–NF35 | 499 | 26-May-2017 | 1-Jun-2017 | USP41–NF36 | USP41–NF36 | Line 2: Change proceed as directed in the test for Delivered Dose Uniformity in Metered-Dose Inhalers and Dry Powder Inhalers, as described in <601>, to: proceed as directed in Inhalation and Nasal Drug Products: Aerosols, Sprays, and Powders—Performance Quality… Read More |
EVENING PRIMROSE OIL CAPSULES | STRENGTH/Analysis | USP40–NF35 | 6952 | 26-May-2017 | 1-Jun-2017 | USP41–NF36 | USP41–NF36 | In the first variable definition list: Change mS = weight of USP Methyl Ester RS in the Standard solution (mg) to: mS = weight of the relevant USP Methyl Ester RS in the Standard solution (mg) |
SORBITOL SOLUTION | ASSAY/Procedure/Analysis | USP39–NF34 | 5897 | 31-Mar-2017 | 1-Apr-2017 | USP41–NF36 | USP41–NF36 | In the variable definition list: Change CU = nominal concentration of Sorbitol Solution in the Sample solution (mg/g) to: CU = concentration of Sorbitol Solution in the Sample solution (mg/g) |
<481> RIBOFLAVIN ASSAY | ASSAY | USP40–NF35 | 386 | 31-Mar-2017 | 1-Apr-2017 | USP41–NF36 | USP41–NF36 | Line 2 of the variable definition list in Chemical Methods, Procedure 1/Analysis: Change sodium hydrofluorite to: sodium hydrosulfite |
<1125> NUCLEIC ACID-BASED TECHNIQUES—GENERAL | APPENDICES/Appendix 1: Regulations and Standards | USP40–NF35 | 1471 | 26-May-2017 | 1-Jun-2017 | USP41–NF36 | USP41–NF36 | Line 1 of bullet 1: Change "Review Criteria for Nucleic Acid Amplification-Based In Vitro Diagnostic Devices for Direct Detection of Infectious Microorganisms" (1993) to: "Nucleic Acid Based In Vitro Diagnostic Devices for Detection of Microbial Pathogens" (2005) |
SUCROSE | SPECIFIC TESTS/Color Value/Analysis | USP40–NF35 | 7938 | 26-May-2017 | 1-Jun-2017 | USP41–NF36 | USP41–NF36 | Line 6 of the variable definition list: Change The absolute difference between two results is NMT 3. to: Suitability requirements Repeatability: The absolute difference between two results is NMT 3. |
VINORELBINE TARTRATE | ADDITIONAL REQUIREMENTS/USP Reference Standards <11> | USP39–NF34 | 6370 | 31-Mar-2017 | 1-Apr-2017 | USP41–NF36 | USP41–NF36 | Line 2 of USP Vinorelbine Related Compound A RS: Change 4-O-Deacetylvinorelbine. to: 4-O-Deacetylvinorelbine tartrate. |
TIMOLOL MALEATE | MULTIPLE SECTIONS | Second Supplement to USP40–NF35 | Online | 28-Jul-2017 | 1-Aug-2017 | USP41–NF36 | USP41–NF36 | The version of the Timolol Maleate monograph which appeared in the Second Supplement to USP 40–NF 35 did not include the revisions approved in the version appearing in the First Supplement to USP 40–NF 35. The version appearing in the First Supplement should be used. The file… Read More
|
<1602> SPACERS AND VALVED HOLDING CHAMBERS USED WITH INHALATION AEROSOLS—CHARACTERIZATION TESTS | 1. INTRODUCTION/1.5 Definitions of Key Terms Relating to This Chapter | USP40–NF35 | 1988 | 31-Mar-2017 | 1-Apr-2017 | USP41–NF36 | USP41–NF36 | Bottom right corner of Figure 1:Change VHC mouthpiece to: Spacer mouthpiece |
ACETYLCYSTEINE SOLUTION | ASSAY/Procedure | USP40–NF35 | 2586 | 26-May-2017 | 1-Jun-2017 | USP41–NF36 | USP41–NF36 | Line 3 of Sample solution: Change Standard stock solution to: Sample stock solution |
METHIONINE | IMPURITIES/Related Compounds | First Supplement to USP40–NF35 | 8337 | 26-May-2017 | 1-Jun-2017 | USP41–NF36 | USP41–NF36 | Row 5 of Column 3 of Table 2: Change 0.1 to: 1.0 |
VINORELBINE INJECTION | ADDITIONAL REQUIREMENTS/USP Reference Standards <11> | USP39–NF34 | 6371 | 31-Mar-2017 | 1-Apr-2017 | USP41–NF36 | USP41–NF36 | Line 2 of USP Vinorelbine Related Compound A RS: Change 4-O-Deacetylvinorelbine. to: 4-O-Deacetylvinorelbine tartrate. |
PENICILLIN G PROCAINE | SPECIFIC TESTS/Content of Penicillin G and Procaine/Analysis | USP40–NF35 | 5607 | 31-Mar-2017 | 1-Apr-2017 | USP41–NF36 | USP41–NF36 | Line 7 of the variable definition list for the first equation: Change CU = concentration of Penicillin G Procaine in the Sample solution (mg) to: CU = concentration of Penicillin G Procaine in the Sample solution (mg/mL) … Read More |
CONSTRUCT HUMAN FIBROBLASTS IN BILAYER SYNTHETIC SCAFFOLD | SPECIFIC TESTS/Metabolic Activity Assessment | USP40–NF35 | 3561 | 26-May-2017 | 1-Jun-2017 | USP41–NF36 | USP41–NF36 | Line 2 of L-Glutamine solution: Change 29.2 g to: 2.92 g |
METHYLDOPA | ASSAY/Procedure/Chromatographic system | First Supplement to USP40–NF35 | 8339 | 26-May-2017 | 1-Jun-2017 | USP41–NF36 | USP41–NF36 | Line 1 of Injection volume: Change 1 mL to: 20 µL |